Fibrobiologics(FBLG.US)

Last Updated 19:00:00 ET
longbridge loading

FibroBiologics Reports Positive Preclinical Results For HDF Spheroids In Treating Burn Wounds

nasdaq·
US
FBLG
-2.78%
US
XBI
+3.88%
US
PBE
+1.60%
nasdaq·
US
FBLG
-2.78%
US
XBI
+3.88%
US
PBE
+1.60%

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

Unusual Whales·
US
FBLG
-2.78%
US
PBE
+1.60%
US
XBI
+3.88%
Unusual Whales·
US
FBLG
-2.78%
US
PBE
+1.60%
US
XBI
+3.88%

EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study

benzinga_article·
US
FBLG
-2.78%
US
BIB
+4.98%
US
XBI
+3.88%
benzinga_article·
US
FBLG
-2.78%
US
BIB
+4.98%
US
XBI
+3.88%

FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens

Tip Ranks·
US
FBLG
-2.78%
US
SBIO
+3.75%
US
BBH
+0.96%
Tip Ranks·
US
FBLG
-2.78%
US
SBIO
+3.75%
US
BBH
+0.96%

FibroBiologics Launches New At-The-Market Equity Offering

Tip Ranks·
US
FBLG
-2.78%
US
BBH
+0.96%
US
LABU
+11.76%
Tip Ranks·
US
FBLG
-2.78%
US
BBH
+0.96%
US
LABU
+11.76%

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update | FBLG Stock News

StockTitan·
US
FBLG
-2.78%
US
PBE
+1.60%
US
BBH
+0.96%
StockTitan·
US
FBLG
-2.78%
US
PBE
+1.60%
US
BBH
+0.96%
© 2026 Longbridge｜Disclaimer